Mallinckrodt sues U.S. health agencies, sees 10% hit to MS treatment sales

Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of its gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as much as 34% on Tuesday.